DCBCI-0901

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameDCBCI-0901
Drug Alias NameMTR-393DCBCI-0901
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitorsMammalian target of Rapamycin (mTORC1) inhibitorsmTOR Complex 2 inhibitors
TargetsPhosphatidylinositol 3 kinase alphaMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesStandard Chem & Pharm Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesStandard Chem & Pharm Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A